Immunic Inc. Stock News

NEW YORK , June 29, 2023 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflamma

New York-based biotechnology company Immunic Inc (NASDAQ:IMUX) has one or more potential blockbusters in its clinical pipeline. The firm's promising lead asset vidofludimus calcium (IMU-838) is an ora

7:55am: Deal or no deal? Wall Street is likely to open in the green as traders return from the Memorial Day long weekend to news that US President Joe Biden and House Speaker Kevin McCarthy reached a

NEW YORK , May 30, 2023 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory

Immunic Inc (NASDAQ:IMUX) has announced the publication of preclinical data highlighting the neuroprotective potential of its investigational drug, vidofludimus calcium (IMU-838). The data confirms t

Immunic, Inc. (NASDAQ:IMUX ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Jessica Breu - Head of Investor Relations & Communications Daniel Vitt - Chief Executive offi

Immunic shares are higher Thursday after the company announced its results for the first quarter ended March 31 and issued a corporate update. "In the first quarter of 2023, we reported outstanding re

– Webcast to be Held at 8:00 am ET on May 11, 2023 – NEW YORK , May 9, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally adminis

Immunic Inc (NASDAQ:IMUX) said it has presented new clinical and pre-clinical data on the molecule IMU-856 at Digestive Disease Week (DDW) 2023 currently underway in Chicago.  The presentation includ

Immunic Inc (NASDAQ:IMUX) said the results from the part C portion of its phase 1 clinical trial of IMU-856 in patients with celiac disease are positive, providing what the company believes as initial

Immunic Inc (NASDAQ:IMUX) has announced the appointment of Dr Richard Rudick to its board of directors, effective April 26, 2023. The biotechnology company developing small molecule therapies for chr

Immunic (IMUX) reports positive results from the maintenance phase of the phase II study evaluating its lead candidate, vidofludimus calcium, to treat patients with ulcerative colitis.

Immunic has caught the attention of market analysts with the release of positive data from the maintenance phase of its Phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patie

Immunic (NASDAQ: IMUX ) stock is getting a boost on Wednesday after the company released results from its Phase 2 CALDOSE-1 Trial. This study had it testing the effectiveness of vidofludimus calcium a

Immunic Inc (NASDAQ:IMUX) has announced positive data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulc